Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERCC1 | P07992 | 1/20 | 0.42 |
| ▸ | FEN1 | P39748 | 1/20 | 0.42 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.42 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.39 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.38 |
| ▸ | CCR1 | P32246 | 1/20 | 0.38 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6094777 | 0.85 | ERCC1 (0.40) | ERCC1FEN1ERCC4LOXL2KCNE1 | |
| SCHEMBL6092543 | 0.77 | KCNE1 (0.41) | KCNE1CCR1KCNQ1MEN1KMT2A | |
| SCHEMBL27616343 | 0.73 | KCNE1 (0.54) | ERCC1FEN1ERCC4KCNE1CCR1 | |
| SCHEMBL5766494 | 0.70 | KMT2A (0.40) | KCNE1CCR1KCNQ1MEN1KMT2A | |
| SCHEMBL826469 | 0.68 | RNASEH1 (0.39) | KMT2AKDM4E | |
| SCHEMBL5644823 | 0.68 | LIPG (0.53) | KCNE1CCR1KCNQ1MEN1KMT2A | |
| Trifluoroacetic Acid SCHEMBL28713743 | 0.66 | LOXL2 (0.64) | LOXL2DPP4KDM4ESMN1; SMN2 | |
| SCHEMBL6017760 | 0.65 | SMN1; SMN2 (0.57) | ERCC1FEN1ERCC4KCNE1CCR1 | |
| SCHEMBL1151004 | 0.65 | KCNE1 (0.65) | ERCC1FEN1ERCC4KCNE1CCR1 | |
| SCHEMBL12471410 | 0.64 | ERCC1 (0.54) | ERCC1FEN1ERCC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7135467-B2 | Pyrimidine carboxamides; 5-hydroxy-2-(2-(1,1-Dioxo-6-[1,2]thiazinan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamides; AIDS; AIDS related complex | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-14 | — | — | US | disclosed |
| US-20040204498-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-14 | — | — | US | disclosed |
| WO-2004062613-A2 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204498-A1 | HIV integrase inhibitors | IMPDH1, TYMP, REV1 | ERCC1 750/4885FEN1 34/4885ERCC4 657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.